Bhide Priya, Chan David Yiu Leung, Ahlström Aisling, Del Campo Laura, Kieslinger Dorit, Lundin Kersti, Park Hannah, Fauque Patricia, Kahraman Semra, Khan Khalid Saeed, Kovacs Peter, Lambalk Cornelis B, Thangaratinam Shakila, Vergouw Carlijn G, van Wely Madelon, Zamora Javier
Wolfson Institute of Population Health, Queen Mary University of London, London, UK
Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
BMJ Open. 2025 Jul 28;15(7):e101761. doi: 10.1136/bmjopen-2025-101761.
Time-lapse imaging (TLI) systems for embryo incubation and assessment are hypothesised to improve the success rates of in vitro fertilisation (IVF) treatment by providing undisturbed culture conditions for embryos and/or providing more information on embryo development (morphokinetic parameters) to improve predictive accuracy for embryo selection. Despite numerous aggregate meta-analyses showing uncertainty of benefit, IVF clinics globally continue to invest significant resources into this technology with little translation of evidence into guidelines or policy frameworks. This may be attributed to heterogeneity in participant populations and/or variations in the use of TLI, as highlighted in the aggregate meta-analyses.
Our research proposal for evidence synthesis using individual participant data meta-analysis will provide greater power than aggregate meta-analysis to detect differential treatment effects for effectiveness (live birth, clinical pregnancy) and safety (pregnancy loss, multiple births, congenital malformations) outcomes across three comparisons (overall effect, undisturbed culture and morphokinetic parameters). We will also analyse if there are specific subgroups of women who may benefit from the intervention and if variations in use of the intervention show any benefits. We have incorporated the results of the literature search used for the latest Cochrane review (7 January 2019) into this review and will include all the trials included therein. We will further update the literature search to include new evidence by searching the electronic databases MEDLINE, EMBASE, CINAHL and CENTRAL from 07/01/2019 to date, outcomes for all ongoing trials reported in the 2019 Cochrane review, trial registers for newer ongoing/completed trials and the citation lists of all the newly identified trials for any relevant references. The search strategy will include a combination of subject headings and text words relating to or describing the participants and the intervention, with no language restrictions. Two authors will independently screen the titles and abstracts, and full text of articles retrieved from the search, to finalise a list of trials suitable for inclusion in the review. We will include randomised controlled trials that assess TLI systems for either undisturbed culture and/or use of morphokinetic parameters for embryo selection in women having IVF/ICSI treatment using their own oocytes.
Ethical approval is not required for this study. We plan to disseminate the findings of the research to all stakeholders, including the National Institute for Health and Care Excellence and other international guideline development groups, through publication in peer-reviewed journals, presentation at conferences, newsletters, meetings and websites of the funders, fertility charities and patient support groups.
CRD42024564332.
用于胚胎培养和评估的延时成像(TLI)系统被认为可以通过为胚胎提供不受干扰的培养条件和/或提供更多关于胚胎发育的信息(形态动力学参数)来提高体外受精(IVF)治疗的成功率,从而提高胚胎选择的预测准确性。尽管众多综合荟萃分析显示其益处存在不确定性,但全球的IVF诊所仍在继续为这项技术投入大量资源,而几乎没有将证据转化为指南或政策框架。正如综合荟萃分析所强调的,这可能归因于参与人群的异质性和/或TLI使用的差异。
我们使用个体参与者数据荟萃分析进行证据综合的研究方案,将比综合荟萃分析更有能力检测三种比较(总体效果、不受干扰的培养和形态动力学参数)中有效性(活产、临床妊娠)和安全性(妊娠丢失、多胎妊娠、先天性畸形)结果的差异治疗效果。我们还将分析是否有特定的女性亚组可能从干预中受益,以及干预使用的差异是否显示出任何益处。我们已将用于最新Cochrane综述(2019年1月7日)的文献检索结果纳入本综述,并将纳入其中的所有试验。我们将进一步更新文献检索,通过搜索2019年1月7日至今的电子数据库MEDLINE、EMBASE、CINAHL和CENTRAL、2019年Cochrane综述中报告的所有正在进行试验的结果、更新的正在进行/完成试验的试验注册库以及所有新识别试验的参考文献列表来纳入新证据。搜索策略将包括与参与者和干预相关或描述参与者和干预的主题词和文本词的组合,无语言限制。两位作者将独立筛选检索到的文章的标题、摘要和全文,以确定适合纳入综述的试验列表。我们将纳入随机对照试验,这些试验评估TLI系统用于接受IVF/ICSI治疗且使用自身卵母细胞的女性的不受干扰的培养和/或使用形态动力学参数进行胚胎选择。
本研究无需伦理批准。我们计划通过在同行评审期刊上发表、在会议上展示、时事通讯、资助者、生育慈善机构和患者支持团体的会议及网站上发布等方式,将研究结果传播给所有利益相关者,包括英国国家卫生与临床优化研究所和其他国际指南制定小组。
PROSPERO注册号:CRD42024564332。